Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Merck KGaA reaffirmed its strong performance ... in February 2025 for treating neurofibromatosis type 1 (NF1), a rare genetic disorder. According to GlobalData’s Pharma Intelligence Center ...

Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.

Illumina & NashBio announce Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery: San Diego Friday, March 21, 2025, 10:00 Hrs [IST] Illumina ...

Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022 Fig 1. Challenges in the management of advanced prostate cancer.

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks ... in patients with the genetic disorder neurofibromatosis type 1 (NF1), a rare genetic condition.

and a $4.2 billion deal with Seattle Genetics covering ADCs for breast cancer and other solid tumours. The deal-making activity signals Merck’s determination to stay at the forefront of cancer ...

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

Increasing Prevalence of Genetic Disorders and Chronic Diseases ... extraction instruments is expected to increase. In June 2023, Merck, known as MSD outside of the United States and Canada ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best immunology stocks to ...